[Protein kinase inhibitors can induce retinopathy]
Johanne Bjerre Lindboe1, Hassan Javed Ahmed, Christos Eleftherios Christakopoulos
1blindboe@hotmail.com.
Abstract:
Novel treatment strategies such as targeted therapy with mitogen-activated protein-kinase-kinase/B-Raf proto-oncogene (MEK/BRAF) inhibitors have prolonged patient survival in metastatic melanoma and are used in oncology. The combination of binimetinib og encorafenib can induce extensive bilateral neuroretinal detachments. In this case report, we present a 72-year-old female patient with this condition. Dilated fundus examination and optical coherence tomography are essential in diagnosis and monitoring of patients treated with MEK/BRAF-inhibitors. No persistent visual deficits were documented in the patient, as this condition appears to be fully reversible.
Insights
Targeted cancer therapies, like MEK/BRAF inhibitors, can cause reversible neuroretinal detachments. This case report highlights the importance of eye exams for patients undergoing such treatments.
Area of Science:
- Oncology
- Ophthalmology
Background:
- Targeted therapies, including mitogen-activated protein-kinase-kinase/B-Raf proto-oncogene (MEK/BRAF) inhibitors, have improved outcomes for metastatic melanoma patients.
- These novel treatments are increasingly utilized in oncological practice.
Related Concept Videos
Inhibition of Cdk Activity
PI3K/mTOR/AKT Signaling Pathway
The JAK-STAT Signaling Pathway
The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...


